29 Feb Provide FDA Indication (include stages), neurotransmitters Affected/Mechanism of Action, and Target Symptoms. Include formulation (Short-acting, intermediate-acting, or long-acting),
- For each medication listed, complete the following:
- Provide FDA Indication (include stages), neurotransmitters Affected/Mechanism of Action, and Target Symptoms.
- Include formulation (Short-acting, intermediate-acting, or long-acting), duration of action, half-life, and CYP 450 enzyme information.
- List notable side effects and precautions.
- Include Patient Education Instructions.
please make sure Font is consistent throughout table, and grammar, spelling, and/or punctuation are accurate.
A total of 4 references needed with intext citation. 2 references provided below. Please use 7th edition APA scholarly references that are witin 5 years.
Stahl, S.M. (2020). Stahl’s essential psychopharmacology: Prescribers guide (7th ed.). Cambridge University Press.
Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
|
Drug Name and Class |
FDA Indication (include stages ) Neurotransmitters Affected/Mechanism of Action Target Symptoms |
Short-acting, intermediate-acting, or long-acting. Duration of Action and Half-life (T1/2), CYP 450 enzyme |
Notable Side Effects/Precautions /Patient Education Instructions |
|
Donepezil (Aricept) |
|||
|
Rivastigmine (Exelon) |
|||
|
Galantamine (Razadyne, Razadyne ER) |
|||
|
Memantine (Namenda) |
